Merck Valuation

Q: What is the Fair Price of MRKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MRKD ($22) is trading below our estimate of [[fair value]] ($48.16)

Is MRKD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MRKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MRKD ($22) is trading below our estimate of fair value ($48.16)

Significantly Below Fair Value: MRKD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRKD?

Key metric: As MRKD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MRKD. This is calculated by dividing MRKD's market cap by their current earnings.
What is MRKD's PE Ratio?
PE Ratio	20.7x
Earnings	US$12.15b
Market Cap	US$252.61b

MRKD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.4x
Enterprise Value/EBITDA	12x
PEG Ratio	1.3x

Price to Earnings Ratio vs Peers

How does MRKD's PE Ratio compare to its peers?

The above table shows the PE ratio for MRKD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.4x
AZN AstraZeneca	31.3x	18.4%	UK£162.4b
ROG Roche Holding	19.1x	11.1%	CHF 204.3b
NOVN Novartis	17.8x	7.0%	CHF 187.3b
JNJ Johnson & Johnson	25.3x	10.6%	US$374.4b
MRKD Merck	20.7x	15.6%	US$252.6b

Price-To-Earnings vs Peers: MRKD is good value based on its Price-To-Earnings Ratio (20.7x) compared to the peer average (23.4x).

Price to Earnings Ratio vs Industry

How does MRKD's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

25 Companies	Price / Earnings	Estimated Growth	Market Cap

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: MRKD is good value based on its Price-To-Earnings Ratio (20.7x) compared to the Global Pharmaceuticals industry average (23.1x).

Price to Earnings Ratio vs Fair Ratio

What is MRKD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRKD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MRKD's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

GSK

UK£54.8b

Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

GSKD

UK£8.80

-17.8%

-1.1%

Novartis

CHF 187.3b

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

NVS

CHF 28,950.00

-1.1%

21.1%

Novartis

CHF 187.3b

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

NVSD

CHF 28.40

n/a